Company intelligence / Profile preview

1st Order Pharmaceuticals

North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Previously developed XEN1101 (Kv7 potassium channel opener), transferred to Xenon Pharmaceuticals after preclinical and early clinical work. XEN1101 has since advanced through Phase 2 and 3 studies for epilepsy. 1st Order’s current pipeline includes the Phase 2 small molecule azetukalner for major depressive disorder

Therapeutic areas: NeurologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Historic out-licensing/sale to Xenon Pharmaceuticals (XEN1101/1OP2198)

Beyond the preview

Go deeper on 1st Order Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1st Order Pharmaceuticals.

Explore the full profile